Clinical trials: Healthy Postmenopausal Women
Menopause, Healthy
Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women
This study is conducted in Europe. The aim of this study is to investigate the bleeding profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)).
- Trial name
- NCT01705249
- Testing
- 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)
- Where
- 19 sites in Norway, Sweden
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Skin Androgenization
A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).
Postmenopausal women will receive testosterone gel or matching placebo gel daily. Sebum excretion rates will be measured before and after 6 weeks of treatment.
- Trial name
- NCT00969163
- Testing
- testosterone gel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
This study will evaluate clinical safety and pharmacokinetics of Maxmarvil® in healthy postmenopausal women
- Trial name
- YY_PK_2011 (NCT01526278)
- Testing
- Maxmarvil®
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yuyu Pharma, Inc.
Postmenopausal Symptoms
A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
The purpose of this study is to examine the effect of two different dose levels of estrogen or placebo in healthy postmenopausal women by measuring the changes in hormone levels and examining the changes in the uterine lining…
- Trial name
- NCT00820664
- Testing
- Comparator: Estrace 0.5 mg, Comparator: Estrace 2 mg
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis
A Phase I Study of AK159 in Healthy Postmenopausal Women
The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.
- Trial name
- NCT01935479
- Testing
- AK159, MN-10-T
- Where
- 3 sites in Japan
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Asahi Kasei Therapeutics Corporation
Menopause
A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy
This is a four-arm, randomized, double-blind, parallel group, placebo-controlled study to compare the effects of two doses of DR-2041(Synthetic Conjugated Estrogens, A) Vaginal Cream on vulvovaginal atrophy in postmenopausal…
- Trial name
- NCT00361569
- Testing
- DR-2041a, DR-2041b
- Where
- 97 sites in United States
- Volunteers
- 622 people
- Sponsor
- Duramed Research
Menopause, Healthy Female Participants
A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects
The two products used in this study are transdermal patches that contain selegiline. The test drug is the Estradiol/Levonorgestrel Transdermal Delivery System (TDS). The comparator drug is the Climara Pro® TDS.
- Trial name
- NCT07794150
- Testing
- Estradiol/Levonorgestrel Transdermal System
- Where
- 2 sites in United States, India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Corium Innovations, Inc.
Osteoporosis
Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
- Trial name
- NCT01011725
- Testing
- MK 0773
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Postmenopause
Study Evaluating Bazedoxifene/CE in Postmenopausal Women
The purpose of this clinical trial is to study the blood levels of a drug (conjugated estrogens) in the body from one dosage form compared to another.
- Trial name
- NCT00550433
- Testing
- Bazedoxifene/Conjugated Estrogens
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Osteopenia
A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women
The main purpose of this study is to assess the safety, tolerability and potential immune response to romosozumab following single subcutaneous (SC; injection under the skin) dose administration in healthy postmenopausal Japanese…
- Trial name
- NCT01101061
- Testing
- Romosozumab
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Amgen
Osteoporotic Fracture
Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A)…
- Trial name
- NCT07178327
- Testing
- LYN101
- Where
- 2 sites in China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanghai TTM-Bio Technology Co., Ltd
Osteopenia
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
- Trial name
- NCT00902356
- Testing
- AMG 167
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Volunteer
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects
This study will be an open-label, non-randomized, absorption, metabolism, and excretion study of [14C]-GDC-0980 administered as a 10-mg oral dose to 6 healthy postmenopausal and/or surgically sterile female subjects following at…
- Trial name
- NCT01487239
- Testing
- [14C]-GDC-0980
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Muscular Atrophy
A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women
The purpose of this study is to establish safe dose levels of ACE-031 in healthy postmenopausal women following multiple dose administration. This study will also evaluate if ACE-031 has an effect on muscle.
- Trial name
- NCT00952887
- Testing
- ACE-031
- Where
- 2 sites in Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Healthy Postmenopausal Women
SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females
This is an Open-label, Sequential dosing, Single Ascending Dose (SAD) Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of KSHN001126 in Healthy Human Post-Menopausal Female Volunteers.
- Trial name
- NCT06467201
- Testing
- KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
- Where
- 2 sites in United States, India
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Amneal Pharmaceuticals, LLC
Healthy Volunteers
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
This study will be a fixed sequence drug-drug interaction study in healthy postmenopausal females, conducted at multiple study sites
- Trial name
- NCT05438303
- Testing
- AZD9833, Midazolam, Omeprazole
- Where
- 2 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Health Postmenopausal Women
Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).
This study will assess the effect of concomitant antacid on the pharmacokinetics and pharmacodynamics of SMC021
- Trial name
- NCT00421590
- Testing
- SMC021
- Where
- Denmark
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis
Osteoporosis
Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once-daily multiple-dose administration of odanacatib (MK0822).
- Trial name
- NCT00769418
- Testing
- odanacatib
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC